A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy

Trial Profile

A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Tivantinib (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms METIV-HCC
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 17 May 2017 According to an ArQule media release, data from this strial will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.
    • 16 May 2017 This trial has been discontinued in Sweden.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top